Keros Therapeutics Inc’s recently made public that its 10% Owner Pontifax Management 4 G.P. (20 unloaded Company’s shares for reported $84.98 million on Oct 15 ’25. In the deal valued at $17.75 per share,4,787,331 shares were sold. As a result of this transaction, Pontifax Management 4 G.P. (20 now holds 0 shares worth roughly $0.0.
Then, ADAR1 Capital Management, LLC sold 5,389,264 shares, generating $95,659,436 in total proceeds. Upon selling the shares at $17.75, the 10% Owner now owns 0 shares.
Before that, Rovaldi Christopher bought 85,306 shares. Keros Therapeutics Inc shares valued at $1,340,157 were divested by the Affiliate at a price of $15.71 per share.
Wells Fargo initiated its Keros Therapeutics Inc [KROS] rating to an Overweight in a research note published on October 20, 2025; the price target was $26. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early June from “a Buy” to “a Neutral”. Cantor Fitzgerald also remained covering KROS and has decreased its forecast on January 21, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Wedbush revised its rating on January 17, 2025. It rated KROS as “a Neutral” which previously was an “an Outperform”.
Price Performance Review of KROS
On Monday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock fall -0.07% to $15.03. Over the last five days, the stock has lost -1.05%. Keros Therapeutics Inc shares have fallen nearly -74.08% since the year began. Nevertheless, the stocks have fallen -5.05% over the past one year. While a 52-week high of $72.37 was reached on 01/02/25, a 52-week low of $9.12 was recorded on 04/09/25.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 14.81, which if violated will result in even more drops to 14.59. On the upside, there is a resistance level at 15.39. A further resistance level may holdings at 15.76.
How much short interest is there in Keros Therapeutics Inc?
A steep rise in short interest was recorded in Keros Therapeutics Inc stocks on 2025-10-15, dropping by -0.8 million shares to a total of 3.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 4.62 million shares. There was a decline of -20.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 16, 2024 when Oppenheimer resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $63.
